PDCD1 and systemic lupus erythematosus: These data demonstrate that the T cell gene signature of patients with SLE can be a marker for distinguishing responders to PD-1 therapy, whereas the T cell gene signature of patients with PS can serve as a marker for distinguishing responders to CTLA-4 therapy.